Effect of cilostazol on endothelial function and platelet function in patients receiving clopidogrel

Effect of cilostazol on endothelial function and platelet function in patients receiving clopidogrel - CSPS.com substudy in TWMU

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026672

Enrollment

Registered

2017-04-01

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-cardiogenic brain infarction

Interventions

Cilostazol 200 mg per day Non cilostazol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-cardiogenic brain infarction within 6 months receiving clopidogrel under consideration of CSPS.com enrollment

Exclusion criteria

Exclusion criteria: Patients who take aspirin or oral anti-coagulant

Design outcomes

Primary

Measure	Time frame
1. Flow-mediated dilatation (% FMD) 2. Thrombus formation and platelet aggregability	—

Countries

Japan

Contacts

Public ContactKazuo Kitagawa

Tokyo Women's Medical University Department of Neurology

kitagawa.kazuo@twmu.ac.jp0333538111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026